# A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma

> **NCT03677141** · PHASE1,PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 117 (actual)

## Conditions studied

- B-cell Non-Hodgkin Lymphoma

## Interventions

- **DRUG:** Mosunetuzumab
- **DRUG:** Polatuzumab Vedotin
- **DRUG:** Rituxumab
- **DRUG:** Cyclophosphamide
- **DRUG:** Doxorubicin
- **DRUG:** Vincristine
- **DRUG:** Prednisone
- **DRUG:** Tocilizumab

## Key facts

- **NCT ID:** NCT03677141
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-08
- **Primary completion:** 2023-10-12
- **Final completion:** 2023-10-12
- **Target enrollment:** 117 (ACTUAL)
- **Last updated:** 2024-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03677141

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03677141, "A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03677141. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*